About

Home

Introduction

Statistics

Programs

Dignet

Gene

GenePair

BioSummarAI

Help & Docs

Documents

Help

FAQs

Links

Acknowledge

Disclaimer

Contact Us

Gene Information

Gene symbol: SERPIND1

Gene name: serpin peptidase inhibitor, clade D (heparin cofactor), member 1

HGNC ID: 4838

Synonyms: HC-II, HLS2, HC2, D22S673

Related Genes

#	Gene Symbol	Number of hits
1	A2M	1 hits
2	C20orf181	1 hits
3	F2	1 hits
4	GPHA2	1 hits
5	HRG	1 hits
6	INS	1 hits
7	PLAT	1 hits
8	SERPINB2	1 hits
9	SERPINC1	1 hits
10	SERPINE1	1 hits

Related Sentences

#	PMID	Sentence
1	2099324	A reduction of heparin cofactor II (HCII) biological activity, despite its normal plasma concentration, is reported in insulin-dependent diabetic patients.
2	2099324	These data demonstrate the presence of a depressed HCII activity in the presence of its normal plasma concentration in insulin-dependent diabetics and suggest a role for short-term metabolic control in conditioning this phenomenon.
3	2099324	A reduction of heparin cofactor II (HCII) biological activity, despite its normal plasma concentration, is reported in insulin-dependent diabetic patients.
4	2099324	These data demonstrate the presence of a depressed HCII activity in the presence of its normal plasma concentration in insulin-dependent diabetics and suggest a role for short-term metabolic control in conditioning this phenomenon.
5	2224144	Heparin cofactor II, histidine-rich glycoprotein, alpha 2-macroglobulin, pre-kallikrein and factor XII had no discriminative power.
6	2347433	Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity.
7	2910581	Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay of antithrombin III.
8	2910581	We compared concentrations of antithrombin III (AT-III) in plasma, as determined by an immunological method and by a functional thrombin inhibition method, in the presence of heparin in 160 blood samples from Type I diabetics.
9	2910581	Although the correlation was highly significant (P less than 0.001) between the results obtained by the two methods, our data demonstrated that results by the thrombin inhibition assay, 121 (SD 15)%, expressed as percentages of the results for a normal plasma pool, were significantly (P less than 0.001) higher than by the immunoreactive method, 104 (SD 15)%, indicating an overestimation of functionally active AT-III.
10	2910581	Concentrations of functionally active AT-III determined by a factor Xa inhibition assay, 105 (SD 13)%, were in the same range as immunoreactive AT-III.
11	2910581	Addition of IgG antiserum to normal pooled plasma quenched only about 90% of the AT-III activity determined by the thrombin inhibition assay, but all of the AT-III activity determined by a factor Xa inhibition assay.
12	2910581	These results demonstrate that the factor Xa inhibition assay is more specific for the determination of AT-III than the thrombin inhibition assay.
13	9788646	Antithrombin III, thrombin-antithrombin III complexes, heparin cofactor II, protein C, protein S, tissue plasminogen activator, (t-PA) D-dimer and plasminogen activator inhibitor (PAI-1 and PAI-2) activities in normal and gestational diabetes pregnancies were determined.
14	9788646	Thrombin-antithrombin III complexes increased and coagulation inhibitors decreased in gestational diabetes.
15	10674414	Dermatan sulphate, heparin cofactor II, and F1+2 peptide in non-insulin-dependent diabetes mellitus.
16	15543340	High heparin cofactor II (HCII) activity has recently been described to protect from coronary instent restenosis, presumably by inactivating thrombin in injured arteries.